hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06288711 id: CHRBSS #STUDY00002538 id: R01DA057308 type: NIH link: https://reporter.nih.gov/quickSearch/R01DA057308 briefTitle: Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD overallStatus: RECRUITING date: 2024-04-30 date: 2027-08-31 date: 2027-11-30 date: 2024-03-01 date: 2024-04-23 name: University of Vermont class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge. The prevalence of PTSD is substantially higher in individuals with OUD than in the general population, with nearly 90% reporting lifetime trauma exposure and 33% meeting diagnostic criteria for PTSD. The primary objective of this study is to evaluate the efficacy of a novel telemedicine-delivered prolonged exposure therapy protocol for improving PE attendance and reducing PTSD symptom severity in individuals with concurrent PTSD and OUD. conditions: Opioid Use Disorder conditions: Posttraumatic Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 135 type: ESTIMATED name: Prolonged exposure therapy name: Financial incentives name: Treatment as usual measure: Prolonged exposure therapy session attendance measure: Prolonged exposure therapy completion measure: Change in posttraumatic stress disorder symptom severity - clinician rated measure: Change in non-prescribed drug use - objective measure: Change in non-prescribed drug use - self-reported measure: Change in opioid craving measure: Medications for opioid use disorder treatment retention measure: Prolonged exposure therapy acceptability measure: Satisfaction with prolonged exposure therapy delivered via telemedicine measure: Prolonged exposure therapy homework adherence measure: Change in posttraumatic stress disorder symptom severity - self-reported sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Vemont status: RECRUITING city: Burlington state: Vermont zip: 05401 country: United States name: Kelly R Peck, Ph.D. role: CONTACT phone: 802-656-9610 email: Kelly.Peck@uvm.edu lat: 44.47588 lon: -73.21207 hasResults: False
nctId: NCT06288698 id: 53955721 briefTitle: Understanding Patient Engagement Trends in TBI Clinical Research overallStatus: NOT_YET_RECRUITING date: 2025-03 date: 2026-03 date: 2027-03 date: 2024-03-01 date: 2024-03-01 name: Power Life Sciences Inc. class: INDUSTRY briefSummary: Clinical trials, specifically focused on TBI, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.
The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients. conditions: TBI studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 500 type: ESTIMATED measure: Number of TBI patients who decide to enroll in a clinical research measure: Rate of TBI patients who remain in clinical trial to trial completion sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Power Life Sciences city: San Francisco state: California zip: 94107 country: United States name: Michael B Gill role: CONTACT phone: 415-900-4227 email: https://www.withpower.com/contact-us@withpower.com lat: 37.77493 lon: -122.41942 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-02-23 uploadDate: 2024-02-23T11:01 filename: ICF_000.pdf size: 69900 hasResults: False
nctId: NCT06288685 id: 73/256 id: 73/256 type: OTHER domain: Police General Hospital briefTitle: Percutaneous Trigger Finger Release Concomitant Steroid Injection Versus Percutaneous Trigger Finger Release Alone overallStatus: COMPLETED date: 2023-10-11 date: 2024-01-23 date: 2024-01-30 date: 2024-03-01 date: 2024-03-12 name: Police General Hospital, Thailand class: OTHER briefSummary: Background:
Percutaneous A1 pulley release is a cost-effective and straightforward procedure with outcomes comparable to open A1 pulley release. Postoperative pain is a prevalent concern. Corticosteroid injection is a common nonoperative treatment for trigger finger, providing favorable outcomes but associated with a notable risk of recurrence. Numerous studies have explored the combined approach of percutaneous trigger finger release with corticosteroid injection. However, to date, there is no report on early postoperative results.
This study constitutes a randomized controlled trial involving patients with trigger finger who underwent percutaneous release surgery from October 2023 to January 2024. A total of 38 patients were enrolled, with 18 assigned to the percutaneous A1 pulley release with steroid injection group and 20 to the percutaneous A1 pulley release alone group. Postoperative assessments included pain scores using the Visual Analog Scale (VAS), evaluation of quality of life through the QuickDASH score (qDASH), patient satisfaction, and complications. conditions: Trigger Finger conditions: Percutaneous A1 Pulley Release conditions: Steroid Injection conditions: Postoperative Pain studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients diagnosed with trigger finger, aged 18 years or older, and classified under Quinell's grade 2, 3, or 4, were included in the study \[ \]. Recruitment took place at the Outpatient Orthopedic Department of the Police General Hospital between October 2023 and January 2024. Exclusion criteria encompassed individuals with a history of prior hand surgery, Dupuytren's disease, type 1 diabetes, previous phalangeal fractures, recent steroid injection within the last month, and autoimmune diseases. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Group allocation and Randomization:
Patients were enrolled and randomized into two groups, percutaneous A1 pulley release with steroid injection (Group A) and percutaneous A1 pulley release alone (Group B), by utilizing computer generate randomization and the results were put in opaque sealed envelopes. Informed consent was obtained from all participants, and surgeries were performed by the same surgeon (WJ). whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 38 type: ACTUAL name: percutaneous A1 pulley release name: Triamcinolone measure: postoperative pain score measure: hand function by quickDASH measure: patients satisfaction sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Police General Hospital city: Bangkok state: Pathumwan zip: 10330 country: Thailand lat: 13.75398 lon: 100.50144 hasResults: False
nctId: NCT06288659 id: KY2024-050 briefTitle: aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial acronym: ASTIM-MT overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-06-30 date: 2026-12-30 date: 2024-03-01 date: 2024-04-23 name: Huashan Hospital class: OTHER briefSummary: ASTIM is a multicenter, prospective, randomised, blinded end-point assessed trial, to investigate the efficacy and safety of treatment based on intracranial pressure monitoring in improving the prognosis of patients with aneurysmal subarachnoid hemorrhage. conditions: Aneurysmal Subarachnoid Hemorrhage conditions: Intracranial Pressure Increase studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 368 type: ESTIMATED name: Intraventricular intracranial pressure monitoring measure: The rate of good neurological functional prognosis measure: The rate of good neurological functional prognosis measure: The rate of good prognosis by Glasgow Outcome Scale-Extended (GOS-E) measure: Mortality measure: Incidence of VP shunt-related hydrocephalus measure: Incidence of Delayed Cerebral Ischemia measure: Incidence of epilepsy measure: Incidence of intracranial infection measure: Incidence of bleeding from puncture site measure: Incidence of poor healing in surgical incisions sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Neurosurgery, Huashan Hospital, Fudan University city: Shanghai state: Shanghai zip: 200000 country: China name: Xuehai Wu, Ph.D. role: CONTACT phone: +8613764880571 email: wuxuehai2013@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06288646 id: ROMEO 101712 briefTitle: Using Infrared Spectroscopy to Analyze Volatile Organic Compounds (VOCs) in the Breath of Patients With Lung Cancer overallStatus: RECRUITING date: 2023-04-24 date: 2024-04-24 date: 2024-12-15 date: 2024-03-01 date: 2024-03-01 name: Picomole Inc class: INDUSTRY name: Vitalite Health Network briefSummary: The goal of this clinical trial is to compare breath samples from patients with lung cancer, those with stable lung nodules, and individuals without lung cancer. The main questions it aims to answer are whether breath patterns are different in these groups and to see if breath patterns change after treatment in patients with lung cancer.
Participants will be asked to provide one breath sample, and two if they get treated. They will also be asked to fill out a questionnaire about their background and medical history. conditions: Lung Cancer conditions: Non Small Cell Lung Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 90 type: ESTIMATED measure: Differences in Breath Spectra of Lung Cancer, Stable Pulmonary Nodules, and Controls measure: Differences in breath spectra of patients with lung cancer before and after treatment sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vitalite Health Network status: RECRUITING city: Moncton state: New Brunswick zip: E1C 8X3 country: Canada name: Nada Hammami role: CONTACT phone: 506-869-7391 email: Nada.Hammami@Vitalitenb.ca name: Marcel Mallet, MD role: PRINCIPAL_INVESTIGATOR lat: 46.09454 lon: -64.7965 hasResults: False
nctId: NCT06288633 id: FNWMRC briefTitle: Cardioneuroablation for Bradyarrhythmia acronym: CARDIOBOOST overallStatus: RECRUITING date: 2024-03-04 date: 2026-02-01 date: 2027-02-01 date: 2024-03-01 date: 2024-03-05 name: Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health class: OTHER name: Meshalkin National Medical Research Center, Ministry of Health of Russian Federation name: The Federal Centre of Cardiovascular Surgery, Russia name: Clinical City Hospital named after I.V. Davydovsky of Moscow Department of Healthcare name: City Clinical Hospital No.52 of Moscow Healthcare Department name: National Medical Research Center for Therapy and Preventive Medicine name: Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan name: Tomsk National Research Medical Center of the Russian Academy of Sciences name: Vishnevsky Center of Surgery name: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation briefSummary: This is a multicenter prospective randomized blind controlled trial with a sham procedure group of the efficacy and safety of cardioneuroablation as a method of treating symptomatic bradycardia without a permanent pacemaker implantation conditions: Bradycardia conditions: Syncope conditions: Sick Sinus Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 106 type: ESTIMATED name: Ganglionated plexi ablation name: Electrophysiological study measure: Implantation of a permanent cardiac pacemaker measure: Complications of cardioneuroablation measure: Presence of symptomatic or asymptomatic rhythm pauses >6 seconds measure: The presence of symptomatic or asymptomatic sinus bradycardia with an average heart rate <40 beats/min in the daytime measure: Transient or permanent atrioventricular block measure: Orthostatic hypotension and/or bradycardia during passive orthostasis test measure: Sinus tachycardia after cardioneuroablation measure: Implantation of a pacemaker by 24 months after randomization sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Almazov National Medical Research Centre status: RECRUITING city: Saint Petersburg country: Russian Federation name: Shlyakhto role: CONTACT phone: +78127023749 lat: 59.93863 lon: 30.31413 hasResults: False
nctId: NCT06288620 id: MA-EBC-II-024 briefTitle: Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer overallStatus: RECRUITING date: 2024-02-25 date: 2025-05-10 date: 2025-05-30 date: 2024-03-01 date: 2024-03-01 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: Microwave Ablative (MWA) therapy, as a minimally invasive thermal therapy, has been attempted to treat breast cancer of small lesions . However, the optimal indications for MWA in the treatment of breast cancer is unknown. This prospective, open-label, single-arm phase II clinical study was conducted to evaluate the efficacy and safety of MWA in the treatment of early-stage unifocal invasive breast cancer, and to explore the immune activating effect. conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 77 type: ESTIMATED name: Microwave Ablation measure: Complete ablation rate measure: Safety of microwave ablation sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the First Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: Jiangsu country: China name: Wenbin Zhou, Professor role: CONTACT lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06288607 id: 2023-SR-708 briefTitle: Safety and Efficacy of High Intensity Focused Ultrasound in Solar Lentigo: A Self-controlled Study overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-16 date: 2024-04-18 date: 2024-04-18 date: 2024-03-01 date: 2024-03-06 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: This trial is a single-center, prospective self-controlled study. The study proposes to recruit 30 patients with solar lentigo on both sides of the face. Patients are randomly assigned to be treated with high-intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China) on one side, and the other side is not treated. The Lab\* values of the lesion area and the area around the lesion are detected separately using 3nh HIGH-QUALITY COLORMETER colorimeter (Konica-Minolta Company, Japan), and skin lesion images are collected with dermatoscope and VISIA® (Canfield Company, USA). Measurements of Lab\* values and related images at the same location, along with adverse events, physician and subjective global aesthetic improvement scale scores are recorded before and at week2, week 4, week6. At the end of the follow-up on the treatment side, the same parameter treatment is provided for the untreated side, and the corresponding observation items are recorded for the patient before treatment, and at week2, week4, and week6 respectively. conditions: Solar Lentigo studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ACTUAL name: High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China) measure: Lab* values measure: Physician Global Aesthetic Improvement Scale measure: Subjective Global Aesthetic Improvement Scale sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University city: Nanjing state: Jiangsu country: China lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06288581 id: UDDS-Pedo-02-2024 briefTitle: U Shaped Toothbrush in Removing Plaque in Children overallStatus: RECRUITING date: 2024-02-01 date: 2024-05-01 date: 2024-08-01 date: 2024-03-01 date: 2024-03-01 name: Damascus University class: OTHER briefSummary: The aim of this study is to evaluate the effectiveness of a U-shaped toothbrush in removing plaque in preschool children which can be a simple, acceptable, and effective way to remove plaque in children in order to improve their oral health in the absence of parental supervision.
The traditional toothbrush group and the U-shaped toothbrush group, All children aged four to five years will have their plaque assessed with the Turesky Modified Quigley Hein Index (TMQH) conditions: Dental Plaque studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Traditional toothbrush group name: U shaped toothbrush group measure: Changing in plaque index sex: ALL minimumAge: 4 Years maximumAge: 5 Years stdAges: CHILD facility: Damascus University status: RECRUITING city: Damascus zip: 20872 country: Syrian Arab Republic name: Kamar Abdulrahman, MSc. student role: CONTACT phone: 00963957510093 email: kamarabdulrahman1@gmail.com lat: 33.5102 lon: 36.29128 hasResults: False
nctId: NCT06288568 id: Shift2Health briefTitle: Night Shift Work and Biomarkers of Obesity Risk in Hospital and Industry Workers acronym: Shift2Health overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-05-01 date: 2028-05-31 date: 2024-03-01 date: 2024-03-05 name: University of Vienna class: OTHER name: Medical University of Vienna name: FH Joanneum Gesellschaft mbH name: Wageningen University and Research name: Wageningen University name: University of Bremen name: Verein zur Förderung des Technologietransfers an der Hochschule Bremerhaven e.V. name: UNIVERSYTET MEDYCZNY W LODZI name: Københavns Universitet name: Charite University, Berlin, Germany name: Erasmus Medical Center briefSummary: Shift work is a well-known risk factor for the development of overweight and obesity, which may lead to downstream effects such as increased risk of cardiometabolic diseases and cancer. However, the biological and behavioral mechanisms underlying the obesogenicity of night shift work are not well understood. Population-based mechanistic studies in real life shift workers are needed to address how night shift work impacts metabolic health.
nctId: NCT06288555 id: 020/2566 briefTitle: Validation of Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening in Primary Care overallStatus: COMPLETED date: 2023-12-21 date: 2024-01-23 date: 2024-01-23 date: 2024-03-01 date: 2024-03-05 name: Ponlawat Hanchana, MD class: OTHER_GOV briefSummary: The goal of this observational study is to assess the accuracy of screening for diabetic peripheral neuropathy by comparing the Ipswich touch test with the 10-g monofilament test in patients diagnosed with type 2 diabetes.
Participants underwent both the Ipswich touch test and the 10-g monofilament test. conditions: Diabetic Foot studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 274 type: ACTUAL name: Ipswich touch test measure: The accuracy of the Ipswich touch test sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ponlawat Hanchana, MD city: Saraburi zip: 18120 country: Thailand lat: 14.53333 lon: 100.91667 hasResults: False
nctId: NCT06288542 id: MD-250-2022 briefTitle: Preoperative Dextrose Infusion and Postoperative Nausea and Vomiting overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-05-01 date: 2024-05-01 date: 2024-03-01 date: 2024-03-01 name: Cairo University class: OTHER briefSummary: This research aims to investigate the efficacy of preoperative intravenous infusion of dextrose 5% during fasting in lowering the incidence and severity of post-operative nausea and vomiting related to laparoscopic gynaecologic procedures conditions: Effect of Dextrose on Postoperative Nausea and Vomiting studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 111 type: ESTIMATED name: group d name: group R measure: frequency of post-opertive nausea and vomiting in 24 hour measure: TOTAL AMOUNT OF ANTIEMETIC REQUIRED sex: FEMALE minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06288529 id: 1 briefTitle: EFFECT SGLT2 INHIBITORS ON CONTRAST MEDIUM INDUCED ACUTE KIDNEY INJURY overallStatus: COMPLETED date: 2023-07-15 date: 2023-12-31 date: 2024-01-31 date: 2024-03-01 date: 2024-03-01 name: University of Health Sciences Balikesir Hospital Eduation and Research class: OTHER_GOV briefSummary: Chronic kidney disease and type 2 diabetes mellitus patients are with in high-risk patients in coronary arterial diseases and increasing number of coronary angiography and coronary interventional procedures have been performed in these population. As well as the risk factors have been identified by many studies preventive measures are lacking.
In our study we found that SGLT2 inhibitors are beneficial in terms of reducing contrast media induced acute kidney injury in both diabetic and CKD patients.This is one of the leading studies in the literature pointing that SGLT2 inhibitors may have a potentially beneficial role in reducing or preventing the development of PC-AKI. conditions: Chronic Kidney Diseases conditions: Type2diabetes studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 975 type: ACTUAL measure: Development of post-contrast acute kidney injury sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Health Sciences Balikesir Education and Research Hospital city: Balıkesir zip: 10100 country: Turkey lat: 39.64917 lon: 27.88611 hasResults: False
nctId: NCT06288516 id: 7484 briefTitle: BenRalizumab Effect on Airway Remodeling in Severe asTHma acronym: BREATH overallStatus: RECRUITING date: 2024-03-01 date: 2025-12-31 date: 2026-06-01 date: 2024-03-01 date: 2024-03-04 name: Aristotle University Of Thessaloniki class: OTHER name: Pulmonary Clinic, Aristotle University of Thessaloniki, Greece name: Pulmonary Clinic, University of Ioannina name: Pulmonary Clinic, Democritus University of Thrace name: 2nd Pulmonary Clinic, Kapodistrian University of Athens name: University Hospital of Crete name: Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens name: University Hospital of Patras briefSummary: Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response. It is important to examine whether these patients have distinct characteristics that could help the treating physician in making the correct diagnosis in clinical practice.